vs
TRICO BANCSHARES （TCBK）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
再鼎医药的季度营收约是TRICO BANCSHARES 的1.2倍（$127.1M vs $109.4M），再鼎医药同比增速更快（17.1% vs 9.0%），TRICO BANCSHARES 自由现金流更多（$127.9M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs 5.4%）
Trico Bancshares是一家总部位于美国的区域银行控股公司，旗下运营Tri Counties Bank，主要为北加利福尼亚州的个人消费者和中小企业提供存款、房贷、小微企业融资、财富管理等各类零售及商业银行服务。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
TCBK vs ZLAB — 直观对比
营收规模更大
ZLAB
是对方的1.2倍
$109.4M
营收增速更快
ZLAB
高出8.1%
9.0%
自由现金流更多
TCBK
多$154.6M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
5.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $109.4M | $127.1M |
| 净利润 | $33.6M | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | 42.6% | -54.6% |
| 净利率 | 251.6% | — |
| 营收同比 | 9.0% | 17.1% |
| 净利润同比 | 15.8% | — |
| 每股收益（稀释后） | $1.02 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收TCBKZLAB
| Q4 25 | $109.4M | $127.1M | ||
| Q3 25 | $107.6M | $115.4M | ||
| Q2 25 | $103.6M | $109.1M | ||
| Q1 25 | $98.6M | $105.7M | ||
| Q4 24 | $100.4M | $108.5M | ||
| Q3 24 | $99.1M | $101.8M | ||
| Q2 24 | $97.9M | $100.1M | ||
| Q1 24 | $98.5M | $87.1M |
净利润TCBKZLAB
| Q4 25 | $33.6M | — | ||
| Q3 25 | $34.0M | $-36.0M | ||
| Q2 25 | $27.5M | $-40.7M | ||
| Q1 25 | $26.4M | $-48.4M | ||
| Q4 24 | $29.0M | — | ||
| Q3 24 | $29.1M | $-41.7M | ||
| Q2 24 | $29.0M | $-80.3M | ||
| Q1 24 | $27.7M | $-53.5M |
毛利率TCBKZLAB
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% | ||
| Q1 24 | — | 61.4% |
营业利润率TCBKZLAB
| Q4 25 | 42.6% | -54.6% | ||
| Q3 25 | 43.2% | -42.3% | ||
| Q2 25 | 36.5% | -50.3% | ||
| Q1 25 | 35.8% | -53.3% | ||
| Q4 24 | 38.7% | -62.6% | ||
| Q3 24 | 39.8% | -66.6% | ||
| Q2 24 | 40.0% | -76.0% | ||
| Q1 24 | 38.3% | -80.7% |
净利率TCBKZLAB
| Q4 25 | 251.6% | — | ||
| Q3 25 | 31.6% | -31.2% | ||
| Q2 25 | 26.6% | -37.3% | ||
| Q1 25 | 26.7% | -45.8% | ||
| Q4 24 | 221.4% | — | ||
| Q3 24 | 29.3% | -40.9% | ||
| Q2 24 | 29.7% | -80.2% | ||
| Q1 24 | 28.2% | -61.4% |
每股收益（稀释后）TCBKZLAB
| Q4 25 | $1.02 | $-0.05 | ||
| Q3 25 | $1.04 | $-0.03 | ||
| Q2 25 | $0.84 | $-0.04 | ||
| Q1 25 | $0.80 | $-0.04 | ||
| Q4 24 | $0.88 | $-0.09 | ||
| Q3 24 | $0.88 | $-0.04 | ||
| Q2 24 | $0.87 | $-0.08 | ||
| Q1 24 | $0.83 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $157.0M | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.3B | $715.5M |
| 总资产 | $9.8B | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资TCBKZLAB
| Q4 25 | $157.0M | $689.6M | ||
| Q3 25 | $298.8M | $717.2M | ||
| Q2 25 | $314.3M | $732.2M | ||
| Q1 25 | $308.3M | $757.3M | ||
| Q4 24 | $145.0M | $779.7M | ||
| Q3 24 | $320.1M | $616.1M | ||
| Q2 24 | $206.6M | $630.0M | ||
| Q1 24 | $82.8M | $650.8M |
股东权益TCBKZLAB
| Q4 25 | $1.3B | $715.5M | ||
| Q3 25 | $1.3B | $759.9M | ||
| Q2 25 | $1.3B | $791.7M | ||
| Q1 25 | $1.3B | $810.8M | ||
| Q4 24 | $1.2B | $840.9M | ||
| Q3 24 | $1.2B | $667.7M | ||
| Q2 24 | $1.2B | $704.2M | ||
| Q1 24 | $1.2B | $762.2M |
总资产TCBKZLAB
| Q4 25 | $9.8B | $1.2B | ||
| Q3 25 | $9.9B | $1.2B | ||
| Q2 25 | $9.9B | $1.2B | ||
| Q1 25 | $9.8B | $1.2B | ||
| Q4 24 | $9.7B | $1.2B | ||
| Q3 24 | $9.8B | $985.3M | ||
| Q2 24 | $9.7B | $987.4M | ||
| Q1 24 | $9.8B | $988.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $133.3M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $127.9M | $-26.7M |
| 自由现金流率自由现金流/营收 | 116.9% | -21.0% |
| 资本支出强度资本支出/营收 | 4.9% | 0.5% |
| 现金转化率经营现金流/净利润 | 3.96× | — |
| 过去12个月自由现金流最近4个季度 | $222.2M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流TCBKZLAB
| Q4 25 | $133.3M | $-26.0M | ||
| Q3 25 | $45.1M | $-32.0M | ||
| Q2 25 | $29.2M | $-31.0M | ||
| Q1 25 | $24.5M | $-61.7M | ||
| Q4 24 | $109.7M | $-55.8M | ||
| Q3 24 | $28.6M | $-26.8M | ||
| Q2 24 | $31.8M | $-42.2M | ||
| Q1 24 | $25.1M | $-90.1M |
自由现金流TCBKZLAB
| Q4 25 | $127.9M | $-26.7M | ||
| Q3 25 | $43.2M | $-35.0M | ||
| Q2 25 | $28.2M | $-33.9M | ||
| Q1 25 | $22.8M | $-63.2M | ||
| Q4 24 | $105.2M | $-58.4M | ||
| Q3 24 | $27.3M | $-28.2M | ||
| Q2 24 | $30.8M | $-42.9M | ||
| Q1 24 | $24.1M | $-91.1M |
自由现金流率TCBKZLAB
| Q4 25 | 116.9% | -21.0% | ||
| Q3 25 | 40.2% | -30.4% | ||
| Q2 25 | 27.2% | -31.1% | ||
| Q1 25 | 23.1% | -59.9% | ||
| Q4 24 | 104.8% | -53.8% | ||
| Q3 24 | 27.6% | -27.7% | ||
| Q2 24 | 31.5% | -42.9% | ||
| Q1 24 | 24.4% | -104.5% |
资本支出强度TCBKZLAB
| Q4 25 | 4.9% | 0.5% | ||
| Q3 25 | 1.7% | 2.6% | ||
| Q2 25 | 1.0% | 2.6% | ||
| Q1 25 | 1.7% | 1.5% | ||
| Q4 24 | 4.5% | 2.4% | ||
| Q3 24 | 1.3% | 1.3% | ||
| Q2 24 | 1.0% | 0.7% | ||
| Q1 24 | 1.0% | 1.1% |
现金转化率TCBKZLAB
| Q4 25 | 3.96× | — | ||
| Q3 25 | 1.33× | — | ||
| Q2 25 | 1.06× | — | ||
| Q1 25 | 0.93× | — | ||
| Q4 24 | 3.78× | — | ||
| Q3 24 | 0.98× | — | ||
| Q2 24 | 1.10× | — | ||
| Q1 24 | 0.90× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
TCBK
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
